Emcure Pharmaceuticals enters into agreement with Sanofi India

17 Jul 2025 Evaluate

Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) have entered into an exclusive distribution and promotion agreement for SIL’s oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the company’s OAD range of products that include well-established brands like Amaryl and Cetapin. 

While SIL will continue to own and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India. There will be no people transition from SIL to Emcure in this arrangement.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.


Emcure Pharma Share Price

1395.15 -9.10 (-0.65%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×